Journal
ALLERGY
Volume 66, Issue 9, Pages 1142-1151Publisher
WILEY
DOI: 10.1111/j.1398-9995.2011.02617.x
Keywords
airway remodeling; allergic asthma; anti-IgE; omalizumab
Categories
Funding
- Novartis Pharma AG
- AstraZeneca
- Boehringer
- Chiesi Pharmaceuticals
- Pfizer
- Novartis
- Nycomed
- MSD
- GSK
- Boehringer Ingelheim
- Roche
- Genentech/Novartis
Ask authors/readers for more resources
Airway remodeling is a central feature of asthma. It is exemplified by thickening of the lamina reticularis and structural changes to the epithelium, submucosa, smooth muscle, and vasculature of the airway wall. Airway remodeling may result from persistent airway inflammation. Immunoglobulin E (IgE) is an important mediator of allergic reactions and has a central role in airway inflammation and asthma-related symptoms. Anti-IgE therapies (such as omalizumab) have the potential to block an early step in the allergic cascade and therefore have the potential to reduce airway remodeling. The reduction in free IgE levels following anti-IgE therapy leads to reductions in high-affinity IgE receptor (Fc epsilon RI) expression on mast cells, basophils, and dendritic cells. This combined effect results in attenuation of several markers of inflammation, including peripheral and bronchial tissue eosinophilia and levels of granulocyte macrophage colony-stimulating factor, interleukin (IL)-2, IL-4, IL-5, and IL-13. Considering the previously demonstrated anti-inflammatory effects of anti-IgE therapy, along with results from a small study showing continued benefit after discontinuation of long-term treatment, a larger study to assess its effect on markers of airway remodeling is underway.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available